Loading
Vir Biotechnology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Mar 2023.
Vir Biotechnology, Inc.: what insiders have been doing
This page follows insider dealings at Vir Biotechnology, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, the company's managers filed 46 filings, from 13 insiders.
The flow runs one way only: 25 sales worth €7.1M, from 7 insiders, and no purchase. Biggest ticket of the year: €1.2M, sold by SVF Endurance (Cayman) Ltd and made public on 26 November 2025.
With 46 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Since 2021, the database holds 4 purchases and 145 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 68.6 m USD and net income at -438.0 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
342
Thresholds
n/a
Buy Volume
€172,916
4 ops. · all time
Sell Volume
€88M
145 ops. · all time
Who traded when
BuySaleVicki L. Sato12 sales
SVF Endurance (Cayman) Ltd11 sales
de Verneuil Vanina7 sales
Brent Sabatini4 sales
Marianne De Backer3 sales
Mark Eisner2 sales
+3 other insiders
Since the insiders bought
- -51.0%Entry US$22.84 · Close at T+365 US$11.19
- -39.9%Entry US$45.94 · Close at T+365 US$27.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vir Biotechnology, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$21.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,148 of 24,148 companies
31.4
score / 100
Value9
Quality54
FCF yld-24%
Earn yld-26%
EV/EBITDA·
ROE-26%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.41
Analyst consensus
9 analystsStrong buy
US$15.00Target US$21.00(+102%)US$30.00
Income statement
RevenueUS$66.5M
Gross profitUS$66.5M100% margin
EBITDA-US$467.8M-703% margin
Net income-US$438M-83.0% margin
Valuation
PER (forward)-4.2x
P/Book1.8x
Beta1.59
Balance sheet & cash
Market capUS$1.8B
Total debtUS$97.9M
Free Cash Flow-US$396.6M
Debt / Equity9%
Profitability & ownership
ROE-26.1%
ROA-14.5%
% insiders6.6%
% institutions84.4%
Last declaration on 17 September 2026
Declarations342 total
19,357 shares@ US$11.000.011% mcap17.8% of flowCommonSEC144:0001959173-26-007020
28,333 shares@ US$11.12630.016% mcap26.0% of flowCommonSEC144:0001959173-26-006814
23,148 shares@ US$10.480.013% mcap20.0% of flowCommonSEC144:0001959173-26-006425
14,352 shares@ US$9.90270.0074% mcap11.7% of flowCommonSEC144:0001959173-26-006413
25,000 shares@ US$9.81190.013% mcap20.1% of flowCommonSEC144:0001959173-26-006329
8,000 shares0Common StockSEC:0001628280-26-056108:1
8,000 shares0Common StockSEC:0001628280-26-056108:0
16,000 shares@ US$10.32120.0088% mcap33.1% of flowCommonSEC144:0001959173-26-004947
8,000 sharesCommon StockSEC:0001628280-26-042326:0
8,000 sharesCommon StockSEC:0001628280-26-042326:1
8,000 shares0Common StockSEC:0001628280-26-038961:0
8,000 shares0Common StockSEC:0001628280-26-038962:0
22,000 shares@ US$10.04660.014% mcap1.9% of flowCommon StockSEC:0001628280-26-029640:0
233,532 shares0Common StockSEC:0001628280-26-029041:1
233,532 shares0Common StockSEC:0001628280-26-029041:0
72,559 shares@ US$9.15632.7% of flowCommon StockSEC:0001628280-26-024098:0
22,000 shares@ US$9.07350.013% mcap1.7% of flowCommon StockSEC:0001628280-26-022971:0
7,711 shares@ US$9.1263.2% of flowCommon StockSEC:0001628280-26-020823:0
2,500 shares0Common StockSEC:0001628280-26-020480:0
21,800 shares@ US$9.50391.7% of flowCommon StockSEC:0001628280-26-013630:0
42,377 shares@ US$1.4850.5% of flowCommon StockSEC:0001628280-26-012397:0
1,430 shares@ US$9.532612.0% of flowCommon StockSEC:0001628280-26-012396:0
1,634 shares@ US$9.53261.3% of flowCommon StockSEC:0001628280-26-012395:0
14,762 shares@ US$9.53266.8% of flowCommon StockSEC:0001628280-26-012390:0
1,616 shares@ US$9.53260.0010% mcap29.0% of flowCommon StockSEC:0001628280-26-012394:0
25 of 342 declarations
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a United States-based biopharmaceutical company listed on the Nasdaq market in the United States, focused on discovering and developing therapies for serious infectious diseases, with a more recent expansion into selected oncology applications. Founded in 2016 and headquartered in San Francisco, California, the company was built around a technology-driven approach that combines antibodies, immunology, and protein-masking platforms to generate differentiated therapeutic candidates. ([stockanalysis.com](https://stockanalysis.com/stocks/vir/company/?utm_source=openai))
From a historical perspective, Vir Biotechnology initially established its identity around high-unmet-need viral diseases. Its portfolio has long included programs in hepatitis B, hepatitis delta, HIV, influenza, and COVID-19, spanning preclinical work through more advanced clinical stages. In its recent communications, the company has signaled a more selective and partnership-oriented strategy, while remaining open to out-licensing discussions for several programs, including hepatitis B, influenza, COVID-19, and HPV. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm?utm_source=openai))
Read moreShow less
In competitive terms, Vir operates in a highly contested field populated by large pharmaceutical companies and numerous specialized biotech peers in immunology and infectious disease. Its competitive edge is centered on the scientific quality of its platform, the depth of its translational research, and its ability to structure partnerships with major industry players. The company has used licensing and collaboration agreements to support asset monetization while reducing the burden of funding the full pipeline on a standalone basis. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai))
Among the most notable recent developments, Vir Biotechnology announced in 2025 first-in-human dosing of VIR-5525, a masked EGFR-targeting T-cell engager for solid tumors, highlighting a diversification beyond infectious diseases. The company also released its 2025 full-year results in 2026, underscoring active capital management and continued clinical progress. For French-speaking investors, the key question remains whether Vir can convert a scientifically promising platform into durable clinical, and eventually commercial, value creation in a highly selective Nasdaq biotech environment. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
